|1.||Schizophrenia (Dementia Praecox)
|2.||Bipolar Disorder (Mania)
|3.||Psychotic Disorders (Schizoaffective Disorder)
|4.||Psychotic Affective Disorders
|1.||Citrome, Leslie: 27 articles (12/2015 - 02/2002)|
|2.||Lieberman, Jeffrey A: 25 articles (07/2014 - 02/2002)|
|3.||Leucht, Stefan: 21 articles (01/2015 - 03/2002)|
|4.||Kane, John M: 20 articles (11/2015 - 09/2002)|
|5.||Lindenmayer, Jean-Pierre: 20 articles (03/2015 - 02/2002)|
|6.||Bossie, Cynthia A: 18 articles (08/2013 - 07/2004)|
|7.||Leucht, S: 17 articles (03/2015 - 01/2000)|
|8.||Meltzer, Herbert Y: 16 articles (08/2015 - 08/2002)|
|9.||McGorry, Patrick D: 16 articles (01/2012 - 12/2002)|
|10.||Volavka, Jan: 14 articles (07/2011 - 02/2002)|
|1.||Antipsychotic Agents (Antipsychotics)IBA
04/01/2011 - "Although it is likely that most, if not all, antipsychotics are effective for schizoaffective disorder, given recent regulatory approval of a specific antipsychotic agent for the acute treatment of schizoaffective disorder, greater attention is now being focused on the entity of schizoaffective disorder and potential treatment decisions. "
06/01/2003 - "While efficacious, their side-effects have been problematic and the approval by the Food and Drug Administration of the newer antipsychotics with improved side-effects profiles heralded important advances in treating psychoses. "
04/01/1991 - "The acute psychoses did not improve with moderate doses of major tranquilizers but resolved completely with drug discontinuation."
05/01/2013 - "Up to now, studies have not demonstrated significant efficacy of antipsychotics on cognitive impairments in patients with psychotic disorders. "
10/01/2004 - "The appearance of the atypical antipsychotics has come as a true 'revolution' in their treatment, owing to the good results obtained in the treatment of the psychoses and the scant deterioration of the motor signs of PD."
|2.||Risperidone (Risperdal Consta)FDA LinkGeneric
04/01/1999 - "The overall positive experience with risperidone has resulted in the drug being widely recommended as a first line treatment option for psychoses."
09/01/2005 - "Oral and long-acting risperidone has been shown to be effective for acute and maintenance treatment of patients with schizoaffective disorders. "
04/01/2002 - "At low doses, risperidone is an effective and well-tolerated treatment for psychoses in elderly patients that improves the quality of life for both patients and their caregivers."
08/01/2001 - "Despite the limitations of the open-label design, the results indicate that risperidone is a safe and effective therapy in combination with mood-stabilizers for the treatment of patients with manic, hypomanic, and depressive symptoms of mixed episodes in schizoaffective disorder, bipolar type."
12/01/2005 - "This open-label, multicentre study investigated the clinical efficacy of liquid peroral risperidone in psychotic disorders, the patients' attitudes toward the study medication vs. previous antipsychotic medication and also psychiatrists' opinion of it. "
|3.||Clozapine (Clozaril)FDA LinkGeneric
01/01/2010 - "Clozapine is the most effective treatment for patients with refractory psychotic disorders and is also effective for reducing suicidal and violent behavior in this same population. "
08/01/1997 - "The atypical antipsychotic clozapine has been reported to be effective in otherwise refractory psychoses. "
04/01/1995 - "Clozapine was an effective treatment for refractory psychotic disorders when given as a part of routine state hospital treatment."
01/01/2002 - "Clozapine has shown consistent efficacy against positive symptoms of psychoses, and emerging reports indicate improvements in aggression and suicidality. "
05/01/1994 - "Advances in the nosology of schizoaffective disorder, emerging epidemiologic data demonstrating large numbers of patients with this disorder in clinical populations, and preliminary evidence that clozapine may have combined antipsychotic and thymoleptic properties as well as efficacy in both the psychotic and affective components of schizoaffective disorder, suggest that renewed interest in the diagnosis and treatment of this disorder may lead to improved delivery of care for this understudied but seriously ill group of patients."
|4.||aripiprazole (Abilify)FDA Link
07/01/2009 - "During combined treatment with mean doses of 22.9 mg of aripiprazole for 9.7 weeks, we assessed a small yet statistically not significant improvement of the psychotic disorder, whereas a marked reduction of obsessions and significant improvements of compulsions could be observed. "
01/01/2010 - "Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report."
06/01/2010 - "The two cases presented raises attention not only to the success of aripiprazole prophylactic treatment, but also to several factors which in the future may aide the clinician in choosing the adequate pharmacological agent (gender, bipolar I disorder, psychotic mixed episodes, partial remission during interepisodes, effectiveness of low dose aripiprazole)."
09/01/2008 - "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting."
05/01/2009 - "The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials."
|5.||olanzapine (Zyprexa)FDA Link
04/01/2001 - "Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. "
04/01/2012 - "The trial evaluated non-acute adult patients with psychotic disorders treated with a stable olanzapine dose who required a treatment change. "
03/01/2011 - "A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls."
08/01/2008 - "Patients with psychotic disorders were consecutively selected from an ongoing, naturalistic study, and divided into two groups according to the following criteria: (1) strict monotherapy with olanzapine (n=19) or (2) no current medication (n=19). "
01/01/2006 - "A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders."
|6.||quetiapine (Seroquel)FDA Link
10/01/2004 - "The administration of quetiapine in doses of 25-50 mg/day brought about an important improvement in the control over the signs of parkinsonian psychoses in our patients. "
01/01/2001 - "Quetiapine is suggested to be effective treatment of youths with psychotic disorders and to have a favorable side-effect profile."
01/01/2007 - "In line with other studies, quetiapine may be considered as an effective treatment for adolescents with a severe psychotic disorder showing a favourable side-effect profile. "
04/01/2000 - "This is the first investigation of the pharmacokinetics, tolerability, and efficacy of quetiapine fumarate in adolescents with chronic or intermittent psychotic disorders. "
04/01/2015 - "The atypical antipsychotic quetiapine has been used in different psychotic and non-psychotic disorders in children and adolescents in randomized clinical trials, open-label studies and chart reviews. "
|7.||Haloperidol (Haldol)FDA LinkGeneric
04/01/1997 - "The present study was undertaken with the aim to compare the efficacy of high and low oral doses of haloperidol in the treatment of acute and transient psychotic disorders. "
01/01/1987 - "Haloperidol, a butyrophenon, is widely used for the treatment of psychotic disorders in man. "
01/01/2015 - "Haloperidol is a neuroleptic drug used for a medication of various psychoses and deliria. "
01/01/2009 - "Haloperidol is extensively used in current psychiatric practice for the treatment of various psychotic disorders. "
06/01/2004 - "While haloperidol is still widely used in the treatment of psychoses, the optimal daily dose remains a topic of controversy, particularly in first-episode psychosis. "
|8.||ziprasidone (Geodon)FDA Link
02/01/2001 - "This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. "
12/01/2011 - "Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile."
07/01/2008 - "In a 24-h, double-blind study, hospitalized patients with psychotic disorder and acute agitation were randomized to treatment with fixed doses of IM ziprasidone: 2 mg (N=38) or 20 mg (N=41). "
07/01/2004 - "The patient was a 15-year-old male adolescent with a history of schizoaffective disorder treated with ziprasidone capsules, 80 mg QD for 8 weeks prior to presentation. "
01/01/2002 - "In addition, intramuscular ziprasidone shows efficacy and good tolerability in the treatment of acute agitation associated with psychotic disorders."
04/01/1987 - "Of the patients with schizoaffective disorder, manic type, 87.5% who received ECT showed "marked improvement"; almost 70% of patients who failed to respond to adequate lithium had "marked improvement" with ECT. "
03/01/1988 - "The study confirmed the efficacy of lithium prophylaxis in broadly defined schizoaffective disorders, but showed that this treatment is relatively ineffective in schizoaffective patients with a prominent schizophrenic-like component in their clinical picture and in those diagnosed cross-sectionally as schizodepressive. "
08/01/1989 - "The efficacy of lithium treatment in preventing relapse in phasal psychoses was tested by the re-examination of 99 patients at a Dresden clinic whose treatment had on average exceeded ten years. "
05/01/1984 - "Lithium-associated remission of psychosis has been described in schizophreniform disorders and in psychotic patients with variants of the red blood cell (RBC)/lithium ratio. "
11/01/2003 - "The major objective of this study was to examine if abnormalities of 5HT2A receptors are associated with bipolar or schizoaffective disorders and if treatment with lithium would cause changes in the 5HT2A receptors. "
|10.||Carbamazepine (Tegretol)FDA LinkGeneric
01/01/1995 - "Carbamazepine may be more effective in patients with schizoaffective and schizophreniform disorders. "
01/01/1991 - "The study was designed to investigate the antimanic profile of carbamazepine as a first-line drug in affective or schizoaffective disorders, to correlate the clinical efficacy with the plasma level of carbamazepine and its 10,11-epoxide metabolite, and to test the potential value of monitoring the salivary level. "
03/01/1992 - "This article reviews current literature on the clinical efficacy of carbamazepine (CBZ) administration in schizophrenic and schizoaffective psychoses. "
02/01/1990 - "A recent study showed an adjuvant effect of carbamazepine in the neuroleptic treatment of acute schizophrenic psychoses. "
10/01/1992 - "[Tegretol as a therapeutic agent for psychotic disorders]."
10/01/2012 - "Antipsychotic long-acting injections (LAIs) reduce covert nonadherence with medication in the clinical management of psychotic disorders. "
02/01/1953 - "[Psychoses treated by pericarotid injections]."
05/01/1952 - "[Intra-cerebral injections and psychoses; one year of therapeutic tests]."
12/01/2013 - "Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder."
05/21/2014 - "Randomized patients (n = 311) were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to be at risk of relapse and likely to benefit from a long-acting injectable antipsychotic. "
|2.||Drug Therapy (Chemotherapy)
10/01/1996 - "Although further controlled studies are required to fully establish the efficacy of the Community Re-Entry Program, these data suggest that brief, focused skills training may play an important role in augmenting optimal pharmacotherapy for hospitalized patients with chronic psychotic disorders."
10/01/2007 - "Our results and studies in other countries seem to indicate that psychological and psychosocial interventions, either alone or in combination with pharmacotherapy, may be effective in at least delaying, if not preventing, the onset of a psychotic disorder."
01/01/2014 - "To analyze the possibility of using immunological parameters for the assessment of the activity of the process and prediction of the quality and completion of remission, we compared the dynamics of clinical and immunological parameters in 76 patients with endogenous attack-like psychoses during pharmacotherapy of a psychotic episode. "
03/01/2004 - "Improved compliance with pharmacotherapy was achieved in treating Hispanic outpatients with psychotic disorders when recognition of culturally based differences between patients and psychiatrists led to modifications in prescribing practices. "
01/30/1964 - "[THE INFLUENCE OF STUDIES OF EEG PATTERNS DURING PSYCHIATRIC PHARMACOTHERAPY ON THE PROGNOSIS OF PSYCHOSES]."
10/01/1995 - "In the two patients with schizoaffective disorder the BPRS improved during the trial, but they had an acute relapse immediately after treatment discontinuation. "
01/01/2009 - "Remission of OCD and depressive episode or psychotic disorder was achieved after treatment with a serotoninergic medication associated with an antipsychotic. "
10/01/1982 - "[A course study on schizophrenic psychoses within the scope of psychiatric before and after care]."
07/01/2009 - "For retraumatization, brief reactive psychosis, depression, depersonalization and derealization, implanted memories, side effects from manipulations of the body, suicide/suicide attempts, hospitalization for physical and mental health problem during or 90 days after treatment, NNH (number needed to harm) > 13,500. "
06/01/1990 - "In the field of remedial exercise and special forms of psychiatric rehabilitation, such as educational and recreational activities, patients with schizophrenic psychosis were evaluated by a doctor and psychologist of the rehabilitation department of the psychiatric sanatorium for after--treatment of psychoses. "
|4.||Length of Stay
11/01/2014 - "Previous contact with child and adolescence psychiatric services, current violent index crime, psychotic disorders, a history of substance, and absconding during treatment predicted longer length of stay. "
10/01/2004 - "Length of stay exceeded 90 days in 9.2% of admissions and 1 year in 0.9% (highest in London and for psychoses). "
02/01/1992 - "Predicting length of stay for patients with psychoses."
03/01/1991 - "The Computerized Psychiatric Severity Index as a predictor of inpatient length of stay for psychoses."
10/01/1975 - "Differences in sex incidence ratios, age at first admission and length of stay are evident between the three psychoses. "
03/01/2014 - "[Nursing care of acute and transient psychotic disorder]."
02/01/2005 - "On the basis of the human rights of patients with psychoses, community psychiatric mental health continuous nursing care holds the core value of "cherishing life, caring for the whole person", and integrates hospital and community medical resources, in order to improve patients' quality of life in the community. "
08/01/1993 - "[Nursing diagnoses and nursing care of persons with psychotic disorders]."
06/01/1978 - "Nursing care study on acute drug induced psychoses, and residual neurotic depression."
06/01/1972 - "[Nursing care of decubitus ulcer in patients with senile psychoses]."